The US FDA’s recommendations for clinical switching study designs and human factors study testing of proposed interchangeable biosimilar products elicited strong, and sometimes divergent, views from the biopharma industry.
In comments on FDA’s January draft guidance, “Considerations in Demonstrating Interchangeability With a Reference Product,” industry groups and companies generally seek more flexibility from FDA on the use of alternative endpoints in switching studies,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?